The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting

被引:91
|
作者
Ciechanover, A [1 ]
机构
[1] Technion Israel Inst Technol, Dept Biochem, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
[2] Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel
关键词
cancer; neurodegeneration; protein degradation; proteasome; ubiquitin;
D O I
10.1042/BST0310474
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Until the early 1980s, protein degradation was a neglected research area, and scientists were mostly busy deciphering the genetic code and its translation to the proteome. Destruction of cellular proteins was thought to be a scavenger, non-specific and dead-end process. Although it was known that proteins do turn over, the large extent and high specificity of the process, whereby distinct proteins have half-lives that range from a few minutes to several days, was not appreciated. The discovery of the lysosome by Christian de Duve did not change this view significantly, as it was clear that this organelle is involved mostly in the degradation of extracellular proteins, and their proteases cannot be substrate-specific. The discovery of the complex cascade of the ubiquitin pathway revolutionized the field. it is clear now that degradation of cellular proteins via the ubiquitin system is a highly complex, temporally controlled and tightly regulated process that plays major roles in a variety of basic pathways and processes during cell life and death, and in health and disease. The system is involved in targeting many cellular proteins, among them cell cycle regulators, growth- and differentiation-controlling factors, transcriptional activators, cell-surface receptors and ion channels, endoplasmic reticulum proteins, antigenic proteins destined for presentation on class I MHC molecules, and abnormal/misfolded proteins. Consequently, it is involved in regulating many basic cellular processes, such as cell cycle and division, growth and differentiation, signal transduction and transcription, modulation of the secretory and endocytic pathways, the immune and inflammatory responses, and quality control. With the multitude of substrates targeted and the numerous processes involved, it is not surprising that aberrations in the pathway have been implicated in the pathogenesis of many diseases, with certain malignancies and neurodegenerative disorders being ranked among them.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 50 条
  • [31] Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions
    Obach, R. Scott
    Walsky, Robert L.
    Venkatakrishnan, Karthik
    [J]. DRUG METABOLISM AND DISPOSITION, 2007, 35 (02) : 246 - 255
  • [32] Transport mechanism-based drug molecular design: Novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells
    Ishikawa, T
    Ikegami, Y
    Sano, K
    Nakagawa, H
    Sawada, S
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (03) : 313 - 325
  • [33] Targeting Human Parainfluenza Virus Type-1 Haemagglutinin-Neuraminidase with Mechanism-Based Inhibitors
    Eveno, Tanguy
    Dirr, Larissa
    El-Deeb, Ibrahim M.
    Guillon, Patrice
    von Itzstein, Mark
    [J]. VIRUSES-BASEL, 2019, 11 (05):
  • [34] Intracellular protein degradation:: From a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting Nobel Lecture
    Ciechanover, Aaron
    [J]. ISRAEL JOURNAL OF CHEMISTRY, 2006, 46 (02) : 121 - 136
  • [35] Intracellular protein degradation: From a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting - (Nobel lecture)
    Ciechanover, A
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2005, 44 (37) : 5944 - 5967
  • [36] Predictive mechanism-based animal models of intraocular neovascular diseases for rapid QSAR drug target identification and validation
    Wong, C
    Hsu, HT
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U192 - U192
  • [37] CRRL290: A Novel and Mechanism-Based Therapeutic Peptide Targeting the Crosstalk Between Angiotensin II and the Natriuretic Peptide System for Cardiorenal Disease
    Ma, Xiao
    Iyer, Seethalakshmi R.
    Reginauld, Shawn
    Pan, Shuchong
    Zheng, Ye
    Cannone, Valentina
    Sangaralingham, Jeson
    Burnett, John C.
    [J]. CIRCULATION, 2021, 144
  • [38] Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing
    Soave, Claire L.
    Guerin, Tracey
    Liu, Jinbao
    Dou, Q. Ping
    [J]. CANCER AND METASTASIS REVIEWS, 2017, 36 (04) : 717 - 736
  • [39] Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing
    Claire L. Soave
    Tracey Guerin
    Jinbao Liu
    Q. Ping Dou
    [J]. Cancer and Metastasis Reviews, 2017, 36 : 717 - 736
  • [40] Targeting microRNAs involved in human diseases: A novel approach for modification of gene expression and drug development
    Gambari, Roberto
    Fabbri, Enrica
    Borgatti, Monica
    Lampronti, Ilaria
    Finotti, Alessia
    Brognara, Eleonora
    Bianchi, Nicoletta
    Manicardi, Alex
    Marchelli, Rosangela
    Corradini, Roberto
    [J]. BIOCHEMICAL PHARMACOLOGY, 2011, 82 (10) : 1416 - 1429